Solana Company
Moat Score — Solana Company
Total Moat Score
6 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Helius holds 15 utility and 21 design patents on the PoNS device, plus new 2025 provisional filings for next-generation technology, and an exclusive worldwide sublicense from Advanced NeuroRehabilitation, giving it real, legally protected differentiation in its niche. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | Helius just transitioned manufacturing from Key Tronic to Minnetronix, a change undertaken to improve production rather than evidence of an existing structural cost advantage over competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | Helius sets a premium list price ($28,270) for PoNS but is simultaneously disputing CMS reimbursement rates it views as inadequate, suggesting its pricing power is constrained by payer dynamics rather than freely set by the company. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | PoNS therapy delivers no network effect; one patient's use of the device does not make it more valuable or effective for another patient. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | The 14-week supervised treatment program creates some clinic and patient commitment once started, but this is a short-term program rather than a durable switching cost, and patients who discontinue face minimal barriers to trying alternative treatments. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Helius is an early-commercial-stage company with a single marketed product and acknowledges that larger, well-capitalized neurostimulation competitors have greater access to capital and established pipelines, limiting its efficient-scale position. |